Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas

Carol J. Wikstrand, Laura P. Hale, Surinder K. Batra, M. Leslie Hill, Peter A. Humphrey, Shekar N. Kurpad, Roger E. McLendon, David Moscatello, Charles N. Pegram, Craig J. Reist, S. Thomas Traweek, Albert J. Wong, Michael R. Zalutsky, Darell D. Bigner

Research output: Contribution to journalArticle

433 Citations (Scopus)

Abstract

Despite molecular biological advances in understanding human cancers, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas. Specific polyvalent antisera to the extracellular portion of the variant were readily induced, but immunization using a synthetic linear peptide representing the unique EGFRvIII primary sequence has been unsuccessful in mice or macaques. We report here five specific monoclonal antibodies (mAbs) developed through long-term immunization protocols using the EGFRvIII-speciflc synthetic peptide and the intact variant in different formats that maintained secondary and tertiary conformation. These mAbs identify the EGFRvIII on the cell surface with relatively high affinity (KA range, 0.13 to 2.5 x 109 m−1) by live cell Scatchard analysis. These mAbs are specific for EGFRvIII as determined by RIA, ELISA, Western blot, analytical flow cytometry, autophosphorylation, and immunohistochemistry. Isolating specific mAbs enabled us to analyze normal and neoplastic human tissue and establish that EGFRvIII is truly tumor specific for subsets of breast carcinomas and for previously reported non-small cell lung carcinomas and gliomas. Also, this receptor is not expressed by any normal human tissues thus far examined, including elements of the peripheral, central nervous, and lymphoid systems. With mAbs, we identified a higher incidence of EGFRvIII positivity in gliomas than previously described and identified an EGFRvIII-positive subset of breast tumors; also, we observed that the EGFRvIII epitope is not expressed in normal tissues, and we demonstrated the localizing and therapeutic potential of the mAbs for tumors expressing this epitope. Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors.

Original languageEnglish (US)
Pages (from-to)3140-3148
Number of pages9
JournalCancer Research
Volume55
Issue number14
StatePublished - Jul 15 1995

Fingerprint

Glioma
Monoclonal Antibodies
Breast Neoplasms
Lung
Neoplasms
Non-Small Cell Lung Carcinoma
Epitopes
Immunization
epidermal growth factor receptor VIII
Central Nervous System Neoplasms
Peptides
Macaca
Tumor Biomarkers
Epidermal Growth Factor Receptor
Immune Sera
Flow Cytometry
Breast
Therapeutics
Central Nervous System
Western Blotting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., ... Bigner, D. D. (1995). Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. Cancer Research, 55(14), 3140-3148.

Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. / Wikstrand, Carol J.; Hale, Laura P.; Batra, Surinder K.; Hill, M. Leslie; Humphrey, Peter A.; Kurpad, Shekar N.; McLendon, Roger E.; Moscatello, David; Pegram, Charles N.; Reist, Craig J.; Traweek, S. Thomas; Wong, Albert J.; Zalutsky, Michael R.; Bigner, Darell D.

In: Cancer Research, Vol. 55, No. 14, 15.07.1995, p. 3140-3148.

Research output: Contribution to journalArticle

Wikstrand, CJ, Hale, LP, Batra, SK, Hill, ML, Humphrey, PA, Kurpad, SN, McLendon, RE, Moscatello, D, Pegram, CN, Reist, CJ, Traweek, ST, Wong, AJ, Zalutsky, MR & Bigner, DD 1995, 'Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas', Cancer Research, vol. 55, no. 14, pp. 3140-3148.
Wikstrand, Carol J. ; Hale, Laura P. ; Batra, Surinder K. ; Hill, M. Leslie ; Humphrey, Peter A. ; Kurpad, Shekar N. ; McLendon, Roger E. ; Moscatello, David ; Pegram, Charles N. ; Reist, Craig J. ; Traweek, S. Thomas ; Wong, Albert J. ; Zalutsky, Michael R. ; Bigner, Darell D. / Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. In: Cancer Research. 1995 ; Vol. 55, No. 14. pp. 3140-3148.
@article{582b013a2818446cb593cb96ceb0a510,
title = "Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas",
abstract = "Despite molecular biological advances in understanding human cancers, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas. Specific polyvalent antisera to the extracellular portion of the variant were readily induced, but immunization using a synthetic linear peptide representing the unique EGFRvIII primary sequence has been unsuccessful in mice or macaques. We report here five specific monoclonal antibodies (mAbs) developed through long-term immunization protocols using the EGFRvIII-speciflc synthetic peptide and the intact variant in different formats that maintained secondary and tertiary conformation. These mAbs identify the EGFRvIII on the cell surface with relatively high affinity (KA range, 0.13 to 2.5 x 109 m−1) by live cell Scatchard analysis. These mAbs are specific for EGFRvIII as determined by RIA, ELISA, Western blot, analytical flow cytometry, autophosphorylation, and immunohistochemistry. Isolating specific mAbs enabled us to analyze normal and neoplastic human tissue and establish that EGFRvIII is truly tumor specific for subsets of breast carcinomas and for previously reported non-small cell lung carcinomas and gliomas. Also, this receptor is not expressed by any normal human tissues thus far examined, including elements of the peripheral, central nervous, and lymphoid systems. With mAbs, we identified a higher incidence of EGFRvIII positivity in gliomas than previously described and identified an EGFRvIII-positive subset of breast tumors; also, we observed that the EGFRvIII epitope is not expressed in normal tissues, and we demonstrated the localizing and therapeutic potential of the mAbs for tumors expressing this epitope. Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors.",
author = "Wikstrand, {Carol J.} and Hale, {Laura P.} and Batra, {Surinder K.} and Hill, {M. Leslie} and Humphrey, {Peter A.} and Kurpad, {Shekar N.} and McLendon, {Roger E.} and David Moscatello and Pegram, {Charles N.} and Reist, {Craig J.} and Traweek, {S. Thomas} and Wong, {Albert J.} and Zalutsky, {Michael R.} and Bigner, {Darell D.}",
year = "1995",
month = "7",
day = "15",
language = "English (US)",
volume = "55",
pages = "3140--3148",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas

AU - Wikstrand, Carol J.

AU - Hale, Laura P.

AU - Batra, Surinder K.

AU - Hill, M. Leslie

AU - Humphrey, Peter A.

AU - Kurpad, Shekar N.

AU - McLendon, Roger E.

AU - Moscatello, David

AU - Pegram, Charles N.

AU - Reist, Craig J.

AU - Traweek, S. Thomas

AU - Wong, Albert J.

AU - Zalutsky, Michael R.

AU - Bigner, Darell D.

PY - 1995/7/15

Y1 - 1995/7/15

N2 - Despite molecular biological advances in understanding human cancers, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas. Specific polyvalent antisera to the extracellular portion of the variant were readily induced, but immunization using a synthetic linear peptide representing the unique EGFRvIII primary sequence has been unsuccessful in mice or macaques. We report here five specific monoclonal antibodies (mAbs) developed through long-term immunization protocols using the EGFRvIII-speciflc synthetic peptide and the intact variant in different formats that maintained secondary and tertiary conformation. These mAbs identify the EGFRvIII on the cell surface with relatively high affinity (KA range, 0.13 to 2.5 x 109 m−1) by live cell Scatchard analysis. These mAbs are specific for EGFRvIII as determined by RIA, ELISA, Western blot, analytical flow cytometry, autophosphorylation, and immunohistochemistry. Isolating specific mAbs enabled us to analyze normal and neoplastic human tissue and establish that EGFRvIII is truly tumor specific for subsets of breast carcinomas and for previously reported non-small cell lung carcinomas and gliomas. Also, this receptor is not expressed by any normal human tissues thus far examined, including elements of the peripheral, central nervous, and lymphoid systems. With mAbs, we identified a higher incidence of EGFRvIII positivity in gliomas than previously described and identified an EGFRvIII-positive subset of breast tumors; also, we observed that the EGFRvIII epitope is not expressed in normal tissues, and we demonstrated the localizing and therapeutic potential of the mAbs for tumors expressing this epitope. Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors.

AB - Despite molecular biological advances in understanding human cancers, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas. Specific polyvalent antisera to the extracellular portion of the variant were readily induced, but immunization using a synthetic linear peptide representing the unique EGFRvIII primary sequence has been unsuccessful in mice or macaques. We report here five specific monoclonal antibodies (mAbs) developed through long-term immunization protocols using the EGFRvIII-speciflc synthetic peptide and the intact variant in different formats that maintained secondary and tertiary conformation. These mAbs identify the EGFRvIII on the cell surface with relatively high affinity (KA range, 0.13 to 2.5 x 109 m−1) by live cell Scatchard analysis. These mAbs are specific for EGFRvIII as determined by RIA, ELISA, Western blot, analytical flow cytometry, autophosphorylation, and immunohistochemistry. Isolating specific mAbs enabled us to analyze normal and neoplastic human tissue and establish that EGFRvIII is truly tumor specific for subsets of breast carcinomas and for previously reported non-small cell lung carcinomas and gliomas. Also, this receptor is not expressed by any normal human tissues thus far examined, including elements of the peripheral, central nervous, and lymphoid systems. With mAbs, we identified a higher incidence of EGFRvIII positivity in gliomas than previously described and identified an EGFRvIII-positive subset of breast tumors; also, we observed that the EGFRvIII epitope is not expressed in normal tissues, and we demonstrated the localizing and therapeutic potential of the mAbs for tumors expressing this epitope. Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors.

UR - http://www.scopus.com/inward/record.url?scp=0029025332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029025332&partnerID=8YFLogxK

M3 - Article

C2 - 7606735

AN - SCOPUS:0029025332

VL - 55

SP - 3140

EP - 3148

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -